piwik-script

    Chair of Biochemistry and Molecular Biology

    AG Wolf

    Contact

    Prof. Dr. Elmar Wolf
    Lehrstuhl für Biochemie und Molekularbiologie
    Biozentrum
    Am Hubland
    97074 Würzburg
    Raum B 353

    Tel:   0931 31-83259
    Fax:  0931 31-84113
    elmar.wolf@biozentrum.uni-wuerzburg.de

    Emmy Noether group - Cancer Systems Biology

    Lab News

    July 2021
    Happy to see our recent paper about the direct role of SPT6 in transcription online at Molecular Cell! Please have a look at the paper and our press release, if you like.

    May 2021
    Bikashs second PROTAC paper is online at the Journal of Medicinal Chemistry. Another great collaboration with the Knapp lab. Well done, Bikash and Anja!“
     
    April 2021
    Congratulations to Julia for a superb defense of her PhD thesis! Looking forward to more of the exciting science with you!
    Many congratulations to the lab of our collaborator Stefan Burdach for their latest paper out now in Blood: MondoA Drives Malignancy through Enhanced Adaptation to Metabolic Stress!

    March 2021
    Excited to be part of a research project about drugging MYC funded by the Alex´s Lemonade Stand Foundation for Childhood Cancer
    https://www.alexslemonade.org/project/drugging-mycn

    December 2020
    Great digital lab retreat together with the Dölken lab - thanks to Lars and his team! here

    September 2020
    Our paper on PROTACs for Aurora-A is online at Nature Chemical Biology. Well done, Bikash! See our paper and press release

    Archive

    Research



    In ageing Western societies tumors are becoming the most relevant medical problem. A key characteristic of tumors is deregulated signaling pathways that significantly alter the transcriptional profile of tumor cells. Proteins of the MYC family play a prominent role in this oncogenic reprogramming as transcription factors.

    Our vision is to understand the transcriptional changes during carcinogenesis and, in particular, the oncogenic function of Myc to the extent that new pharmaceutical strategies for the fight against cancer can be developed on this basis. To this end, my research group uses genome- and proteome-wide methods to better understand the biology of tumors as well as genetic screens to find potential therapeutic targets of tumor cells. Together with our partners, we have recently developed substances that inhibit the function of Myc. In the next few years, we want to improve these molecules, of the PROTAC substance class, to such an extent that they can be clinically tested and applied.


    Research topic 1: The oncogenic function of MYC

    Research topic 2: Investigation of transcriptional elongation

    Research topic 3: New pharmaceutical concepts in oncology

    Publications

    Recent:

    Narain A, Bhandare P, Adhikari B, Backes S, Eilers M, Dölken L, Schlosser A, Erhard F, Baluapuri A, Wolf E, Targeted protein degradation reveals a direct role of SPT6 in RNAPII elongation and termination, Molecular Cell, 2021, 10.1016/j.molcel.2021.06.016

    Dölle A, Adhikari B, Krämer A, Weckesser J, Berner N, Berger LM, Diebold M, Szewczyk MM, Barsyte-Lovejoy D, Arrowsmith CH, Gebel J, Löhr F, Dötsch V, Eilers M, Heinzlmeir S, Kuster B, Sotriffer C, Wolf E*, Knapp S*, Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders, Journal of Medicinal Chemistry, 2021, doi: 10.1021/acs.jmedchem.1c00146   

    Adhikari B, Bozilovic J, Diebold M,Schwarz JD, Hofstetter J, Schröder M, Wanior M, Narain A, Vogt M, DudvarskiStankovic N, Baluapuri A, Schönemann L, Eing L, Bhandare P, Kuster B, SchlosserA, Heinzlmeir S, Sotriffer C, Knapp S* WolfE*, PROTAC-mediated degradation reveals a non-catalytic function ofAURORA-A kinase, Nature Chemical Biology, 2020,

    Sipol A, Hameister E, Xue B, Hofstetter J, Barenboim M, ÖllingerR, Jain G, Prexler C, Rubio RA, Baldauf MC, Franchina DG, Petry A, Schmäh J, ThielU, Gorlach A, Cario G, Brenner D, Richter G, Grünewald TGP, Rad R, Wolf E, RulandJ, Sorensen PH, Burdach SEG, MondoA Drives B-ALL Malignancy through EnhancedAdaptation to Metabolic Stress, Blood, 2021, DOI: 10.1182/blood.2020007932

    Wolpaw AJ, Bayliss R, Büchel G, Dang CV, Eilers M, Gustafson WC, Hansen GM, Jura N, Knapp S, Lemmon MA, Levens D, Maris JM, Marmorstein R, Metallo SJ, Park JR, Penn LZ, Rape M, Roussel MF, Shokat KM, Tansey WP, Verba KA, Vos SM, Weiss WA, Wolf E, Mossé YP (2021) Drugging the 'undruggable' MYCN oncogenic transcription factor: Overcoming previous obstacles to impact childhood cancers, Cancer Research,  doi: 10.1158/0008-5472.CAN-20-3108

    Endres T, Solvie D, Heidelberger J ,Andrioletti V ,Baluapuri A ,Ade CP, Muhar M, Eilers U, Vos SM, Cramer P, Zuber J, Beli P, Popov N, Wolf E, Gallant P, Eilers M: Ubiquitylation of MYC couples transcription elongation with double-strand break repair at active promoters, Molecular Cell, in press

    Hartmann O, Reissland M, Maier CR, Fischer T, Prieto-Garcia C, Baluapuri A, Schwarz J, Schmitz W, Garrido-Rodriguez M, Pahor N, Davies CC, Bassermann F, Orian A, Wolf E, Schulze A, Calzado MA, Rosenfeldt MT, Diefenbacher ME, Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease. Front Cell Dev Biol. 2021,9

    Jessen C, Kreß JKC, Baluapuri A, Hufnagel A, Schmitz W,Kneitz S, Roth S, Marquardt A, Appenzeller S, Ade CP, Glutsch V, Wobser M,Friedmann-Angeli JP, Mosteo L, Goding CR, Schilling B, Geissinger E, Wolf E, Meierjohann S, The transcriptionfactor NRF2 enhances melanoma malignancy by blocking differentiation andinducing COX2 expression, Oncogene, 2020, doi:10.1038/s41388-020-01477-8

    Wolf E and Eilers M: Targeting MYC Proteins for Tumor Therapy, Annual Review of Cancer Biology, 2020, 4

    Show all

    Link to all Publications in PubMed